OncoMatch/Clinical Trials/NCT05473910
A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)
Is NCT05473910 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including SOC + TSC-101 and SOC + TSC-100 for aml.
Treatment: SOC + TSC-101 · SOC + TSC-100 — This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: HLA-A a*0201 expression
Participants in the treatment arms must express HLA-A*0201
Required: HA-1 positive genotype
Having the HA1+/- or HA-1+/+ (HA-1 positive) genotype to be eligible for TSC-100 treatment
Required: HA-2 positive genotype
Having the HA2+/- HA-2+/+ (HA-2 positive) genotype to be eligible for TSC-101 treatment
Excluded: HLA-A a*02:07 expression
Participants who meet inclusion criteria for TSC-101 but who are also positive for HLAA*02:07
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: prior allogeneic hematopoietic cell transplant
Prior allogeneic HCT
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- University of Colorado - Anschutz Cancer Center · Aurora, Colorado
- SCRI - Colorado Blood Cancer Institute · Denver, Colorado
- Yale · New Haven, Connecticut
- Memorial Cancer Institute · Hollywood, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05473910 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior prior allogeneic hematopoietic cell transplant disqualifies patients from enrollment.
Does this trial require HLA-A?
Yes, HLA-A a*0201 expression is a required biomarker for enrollment.
Does this trial require HA-1?
Yes, HA-1 positive genotype is a required biomarker for enrollment.
Does this trial require HA-2?
Yes, HA-2 positive genotype is a required biomarker for enrollment.
Are patients with HLA-A alterations eligible?
No. HLA-A a*02:07 expression is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify